FDA Approves Risankizumab (Skyrizi) for Psoriatic Arthritis FDA Approves Risankizumab (Skyrizi) for Psoriatic Arthritis

The approval is the second indication for the anti-interleukin 23 monoclonal antibody after approval for plaque psoriasis was granted in 2019.News Alerts
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Rheumatology News Alert Source Type: news